Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide Added to Ixekizumab in Plaque Psoriasis and Obesity/Overweight
NCT06857942Phase 4Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Primary completion
- May 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tirzepatide in plaque psoriasis and obesity, sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants Achieving Dermatology Life Quality Index (0,1) at 12 months and Percentage of Participants Achieving at least 10% Weight Reduction at 12 months. Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
plaque psoriasisobesity
Beyond the preview
Go deeper on NCT06857942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857942.